AI Correctly Localized Almost One-Third of Interval Cancers on Screening Digital Breast Tomosynthesis

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on July 31, 2025.

via HealthDay

THURSDAY, July 31 Aug. 1, 2025 -- Artificial intelligence (AI) correctly localized nearly one-third of interval cancers on retrospective evaluation of screening digital breast tomosynthesis (DBT) examinations, according to a study published online July 29 in Radiology.

Manisha Bahl, M.D., M.P.H., from Massachusetts General Hospital in Boston, and colleagues examined the performance of an AI algorithm in detecting and localizing interval cancers at screening DBT and validated the diagnostic threshold of the algorithm. Screening DBT examinations performed immediately before confirmed interval cancer diagnoses were retrospectively analyzed by a U.S. Food and Drug Administration-cleared AI algorithm. Lesions marked by AI on DBT sections were assigned a score from 0 to 100. Two breast imaging radiologists independently reviewed AI-positive examinations (score ≥10) to examine whether AI annotations corresponded with the site of subsequent cancer.

The researchers found that AI correctly localized 32.6 percent of 224 interval cancers in 224 women at retrospective evaluation of the screening DBT examinations. Larger size at surgical pathology (37 versus 22 mm) and axillary lymph node positivity (41.3 versus 22.8 percent) were features associated with interval cancers detected by AI. AI correctly localized 84.4 percent of screening-detected cancers using the same threshold (score ≥10), and correctly classified 85.9 and 73.3 percent of true-negative and false-positive cases as negative.

"Our study shows that an AI algorithm can retrospectively detect and correctly localize nearly one-third of interval breast cancers on screening DBT exams, suggesting its potential to reduce the interval cancer rate and improve screening outcomes," Bahl said in a statement.

One author disclosed ties to industry; the study was funded by Lunit.

Abstract/Full Text

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-08-01 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords